Evidence map›Paper›PMID 25926417›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2015

Assessment of ToxCast Phase II for Mitochondrial Liabilities Using a High-Throughput Respirometric Assay.

Lauren P Wills, Gyda C Beeson, Douglas B Hoover, Rick G Schnellmann, Craig C Beeson

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Progeny effects of rotenone exposure depend on parental toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Antimicrobial agents and chemotherapy · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Next Generation Blueprint of Computational Toxicology at the U.S. Environmental Protection Agency.Toxicological sciences : an official journal of the Society of Toxicology · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Mitochondrial Toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lauren P Wills*MitoHealth Inc., Charleston, South Carolina.
Gyda C Beeson*MitoHealth Inc., Charleston, South Carolina, Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and.
Douglas B HooverDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and.
Rick G SchnellmannDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina.
Craig C Beeson*MitoHealth Inc., Charleston, South Carolina, Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and beesonc@musc.edu.
MitoHealth (United States) · USMedical University of South Carolina · USRalph H. Johnson VA Medical Center · US

Funding

Mitochondrial Biogenesis Promotes Recovery From Oxidant InjuryR01GM084147 · NIGMS · UNIVERSITY OF ARIZONA · PI SCHNELLMANN, RICK G · 2008 to 2016
$2.4M
High Throughput Mitochondrial Nephrotoxicant AssayR44ES019378 · NIEHS · MITOHEALTH, INC. · PI BEESON, CRAIG CANO · 2011 to 2012
$1.6M
NIEHS NIH HHS R44 ES019378NIGMS NIH HHS R01 GM084147
6 · The paper itself

Abstract

Previous high-throughput screens to identify mitochondrial toxicants used immortalized cell lines and focused on changes in mitochondrial membrane potential, which may not be sufficient and do not identify different types of mitochondrial dysfunction. Primary cultures of renal proximal tubule cells (RPTC) were examined with the Seahorse Extracellular Flux Analyzer to screen 676 compounds (5 μM; 1 h) from the ToxCast Phase II library for mitochondrial toxicants. Of the 676 compounds, 19 were classified as cytotoxicants, 376 were electron transport chain (ETC) inhibitors, and 5 were uncouplers. The remaining 276 compounds were examined after a 5-h exposure to identify slower acting mitochondrial toxicants. This experiment identified 3 cytotoxicants, 110 ETC inhibitors, and 163 compounds with no effect. A subset of the ToxCast Phase II library was also examined in immortalized human renal cells (HK2) to determine differences in susceptibility to mitochondrial toxicity. Of the 131 RPTC ETC inhibitors tested, only 14 were ETC inhibitors in HK2 cells. Of the 5 RPTC uncouplers, 1 compound was an uncoupler in HK2 cells. These results demonstrate that 73% (491/676) of the compounds in the ToxCast Phase II library compounds exhibit RPTC mitochondrial toxicity, overwhelmingly ETC inhibition. In contrast, renal HK2 cells are markedly less sensitive and only identified 6% of the compounds as mitochondrial toxicants. We suggest caution is needed when studying mitochondrial toxicity in immortalized cell lines. This information will provide mechanisms and chemical-based criteria for assessing and predicting mitochondrial liabilities of new drugs, consumer products, and environmental agents.

Indexed as

High-Throughput Screening AssaysToxicity TestsAnimalsCell LineCell RespirationElectron TransportFemaleHumansMitochondriaRabbitscell culturein vitro and alternatives, kidneysafety evaluationsystems toxicology

Identifiers

PMID25926417
PMCPMC5009421
OpenAlexW2147420977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.